DK1305014T3 - Anvendelse af (deaminohydroxy)toremifen til behandling af vaginal törhed eller seksuel dysfunktion hos kvinder under eller efter menopausen - Google Patents

Anvendelse af (deaminohydroxy)toremifen til behandling af vaginal törhed eller seksuel dysfunktion hos kvinder under eller efter menopausen

Info

Publication number
DK1305014T3
DK1305014T3 DK01931746T DK01931746T DK1305014T3 DK 1305014 T3 DK1305014 T3 DK 1305014T3 DK 01931746 T DK01931746 T DK 01931746T DK 01931746 T DK01931746 T DK 01931746T DK 1305014 T3 DK1305014 T3 DK 1305014T3
Authority
DK
Denmark
Prior art keywords
treatment
deaminohydroxy
menopause
toremifene
sexual dysfunction
Prior art date
Application number
DK01931746T
Other languages
English (en)
Inventor
Kaija Halonen
Lauri Kangas
Michael W Degregorio
Original Assignee
Hormos Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24504996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1305014(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Corp filed Critical Hormos Medical Corp
Application granted granted Critical
Publication of DK1305014T3 publication Critical patent/DK1305014T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01931746T 2000-07-21 2001-05-02 Anvendelse af (deaminohydroxy)toremifen til behandling af vaginal törhed eller seksuel dysfunktion hos kvinder under eller efter menopausen DK1305014T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625,199 US6245819B1 (en) 2000-07-21 2000-07-21 Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
PCT/FI2001/000414 WO2002007718A1 (en) 2000-07-21 2001-05-02 Method for the treatment of climacteric disorders in women during or after the menopause

Publications (1)

Publication Number Publication Date
DK1305014T3 true DK1305014T3 (da) 2005-08-22

Family

ID=24504996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01931746T DK1305014T3 (da) 2000-07-21 2001-05-02 Anvendelse af (deaminohydroxy)toremifen til behandling af vaginal törhed eller seksuel dysfunktion hos kvinder under eller efter menopausen

Country Status (30)

Country Link
US (5) US6245819B1 (da)
EP (1) EP1305014B1 (da)
JP (2) JP5575351B2 (da)
KR (1) KR100880564B1 (da)
CN (1) CN1287775C (da)
AT (1) ATE300289T1 (da)
AU (2) AU2001258449B2 (da)
BG (1) BG65943B1 (da)
BR (1) BR0112659A (da)
CA (1) CA2416480C (da)
CY (1) CY1105370T1 (da)
CZ (1) CZ299439B6 (da)
DE (1) DE60112301T2 (da)
DK (1) DK1305014T3 (da)
EE (1) EE05344B1 (da)
ES (1) ES2241819T3 (da)
HR (1) HRP20030024A2 (da)
HU (1) HU229361B1 (da)
IL (1) IL153823A (da)
MX (1) MXPA03000378A (da)
NO (1) NO329954B1 (da)
NZ (1) NZ524181A (da)
PL (1) PL202654B1 (da)
PT (1) PT1305014E (da)
RU (1) RU2268035C2 (da)
SI (1) SI1305014T1 (da)
SK (1) SK287096B6 (da)
UA (1) UA74386C2 (da)
WO (1) WO2002007718A1 (da)
ZA (1) ZA200300342B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU2001261244B2 (en) * 2000-05-09 2006-08-03 Nitromed, Inc. Infrared thermography and methods of use
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
CN100448437C (zh) * 2002-06-06 2009-01-07 霍尔莫斯医疗有限公司 抑制女性萎缩或治疗或预防与女性萎缩相关的症状的方法
JP2006515276A (ja) * 2002-10-22 2006-05-25 オスコテック株式会社 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
CA2565134C (en) 2004-05-04 2013-05-21 Veli-Matti Lehtola Novel oral formulations of ospemifene
KR100734942B1 (ko) 2007-01-02 2007-07-03 김재현 여성 갱년기 증후군에 유효한 건강기능식품 조성물
EP2121553B1 (en) * 2007-02-14 2012-06-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
RU2535112C2 (ru) * 2012-09-19 2014-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия министерства здравоохранения и социального развития" Способ лечения климактерических и урогенитальных расстройств у женщин в постменопаузе на фоне гипотириоза
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
MX2017011469A (es) 2015-03-10 2018-01-23 Shionogi Inc Dispersiones sólidas.
WO2016149675A1 (en) * 2015-03-19 2016-09-22 Epstein Wendy Anne Compounds and forms of treatment for female sexual disorders
RU2636619C1 (ru) * 2017-02-20 2017-11-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения вагинальной атрофии у женщин в постменопаузе с учетом состояния эпителия и микробиоценоза влагалища

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352699A (en) 1992-04-30 1994-10-04 University Of Massachusetts Medical Center Use of retinioc acid to treat vaginal atrophy
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
RU2342145C2 (ru) 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
US20010034340A1 (en) 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

Also Published As

Publication number Publication date
US20030036566A1 (en) 2003-02-20
PT1305014E (pt) 2005-09-30
CA2416480A1 (en) 2002-01-31
WO2002007718A8 (en) 2002-11-14
KR100880564B1 (ko) 2009-01-30
NO20030273D0 (no) 2003-01-20
IL153823A0 (en) 2003-07-31
WO2002007718A1 (en) 2002-01-31
US6245819B1 (en) 2001-06-12
EP1305014B1 (en) 2005-07-27
US6984665B2 (en) 2006-01-10
BG107472A (bg) 2003-11-28
CZ200326A3 (cs) 2003-05-14
KR20030048378A (ko) 2003-06-19
UA74386C2 (uk) 2005-12-15
HUP0301791A3 (en) 2008-01-28
PL202654B1 (pl) 2009-07-31
US20100280131A1 (en) 2010-11-04
AU5844901A (en) 2002-02-05
US9566252B2 (en) 2017-02-14
JP2004504345A (ja) 2004-02-12
ES2241819T3 (es) 2005-11-01
ATE300289T1 (de) 2005-08-15
NZ524181A (en) 2003-07-25
CN1446085A (zh) 2003-10-01
US20140142195A1 (en) 2014-05-22
HU229361B1 (en) 2013-11-28
DE60112301T2 (de) 2006-05-24
CY1105370T1 (el) 2010-04-28
RU2268035C2 (ru) 2006-01-20
NO329954B1 (no) 2011-01-31
US20050272825A1 (en) 2005-12-08
DE60112301D1 (de) 2005-09-01
MXPA03000378A (es) 2003-09-22
PL359506A1 (en) 2004-08-23
AU2001258449B2 (en) 2004-07-29
CZ299439B6 (cs) 2008-07-30
SK287096B6 (sk) 2009-12-07
ZA200300342B (en) 2004-02-13
HRP20030024A2 (en) 2006-12-31
SI1305014T1 (sl) 2005-12-31
JP5629746B2 (ja) 2014-11-26
EP1305014A1 (en) 2003-05-02
HUP0301791A2 (hu) 2003-12-29
BG65943B1 (bg) 2010-06-30
EE05344B1 (et) 2010-10-15
IL153823A (en) 2008-03-20
CN1287775C (zh) 2006-12-06
JP2013060445A (ja) 2013-04-04
SK16072002A3 (sk) 2003-06-03
JP5575351B2 (ja) 2014-08-20
EE200300031A (et) 2004-10-15
BR0112659A (pt) 2003-06-24
CA2416480C (en) 2009-12-08
HK1056694A1 (en) 2004-02-27
NO20030273L (no) 2003-01-20

Similar Documents

Publication Publication Date Title
EE05344B1 (et) Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
RU2003105159A (ru) Способ лечения климактерических расстройств у женщин во время или после менопаузы
DK1578427T3 (da) Anvendelse af GnRH-agonister til understötning af den luteale fase ved infertilitetsbehandling
EA200201000A1 (ru) Гормон-заместительная терапия
TNSN07147A1 (fr) Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
BRPI0509086A (pt) uso de inibidores de pde iii para redução do tamanho do coração em mamìferos sofrendo de parada cardìaca
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
BRPI0507661A (pt) método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo
BR0317555A (pt) Composições farmacêuticas de sertaconazol para uso vaginal
IL164528A (en) Method for inhibition of atrophy or for treatment or prevention of atrophy related symptoms in women
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
RU2006133903A (ru) Способ лечения или профилактики остеопороза у индивидуумов с высоким обменом костной ткани
BRPI0416202A (pt) formulações inibidoras de fosfodiesterase v
MX2024002892A (es) Azalidos inmunomoduladores.
AR044095A1 (es) Composicion farmaceutica que comprende un antagonista del receptor de la hormona del crecimiento y un antihipertensivo y uso de los mismos para prepararla
CL2008002362A1 (es) Composicion farmaceutica vaginal que comprende menor igual que 13 mg de dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-en-3beta, 17 beta-diol o 4androsten-3, 17-diona y un excipiente; kit; uso para tratar sintomas menopausicos como incontinencia urinaria, vaginitis atrofica, sequedad vaginal, dispareunia y disfuncion sexual.
UY27115A1 (es) Uso de gestágenos para inhibir la maduración acelerada del endometrio durante el tratamiento de la infertilidad